Martel Céline, Labrie Fernand, Archer David F, Ke Yuyong, Gonthier Renaud, Simard Jean-Nicolas, Lavoie Lyne, Vaillancourt Mario, Montesino Marlene, Balser John, Moyneur Érick
EndoCeutics Inc., Quebec City, QC G1V 4M7, Canada.
EndoCeutics Inc., Quebec City, QC G1V 4M7, Canada.
J Steroid Biochem Mol Biol. 2016 May;159:142-53. doi: 10.1016/j.jsbmb.2016.03.016. Epub 2016 Mar 10.
This study integrates all data obtained in women aged 40-80years enrolled with moderate to severe symptoms of vulvovaginal atrophy (VVA) who received daily intravaginal administration of 0.50% (6.5mg) dehydroepiandrosterone (DHEA; prasterone) for 12weeks (n=723; ITT-S population) as compared with placebo (n=266; ITT-S population). To this end, serum steroid levels (DHEA, DHEA-sulfate (DHEA-S), androst-5-ene-3β, 17β-diol (5-diol), testosterone, dihydrotestosterone (DHT), androstenedione (4-dione), estrone (E1), estradiol (E2), estrone sulfate (E1-S), androsterone glucuronide (ADT-G), and androstane-3α, 17β-diol 17-glucuronide (3α-diol-17G)) were measured at Day 1 and Week 12 by liquid chromatography-tandem mass spectrometry (LC-MS/MS) following validation performed according to the FDA guidelines [1-6]. In agreement with the mechanisms of intracrinology where DHEA is exclusively transformed intracellularly into active sex steroids which act and are inactivated locally before being released as glucuronided or sulfated metabolites for elimination by the kidneys and liver, all sex steroids remained well within normal postmenopausal values following administration of intravaginal DHEA. Serum estradiol, the most relevant sex steroid, was measured after 12weeks of treatment at 3.36pg/ml (cITT-S population) or 19% below the normal postmenopausal value of 4.17pg/ml. On the other hand, serum E1-S, the best recognized marker of global estrogenic activity, shows an average value of 209pg/ml at 12 weeks compared to 220pg/ml in normal postmenopausal women. Moreover, serum ADT-G, the main metabolite of androgens, also remains well within normal postmenopausal values. The present data shows that a low daily intravaginal dose (6.5mg) of DHEA (prasterone) which is efficacious on the symptoms and signs of VVA, permits to achieve the desired local efficacy without systemic exposure, in agreement with the stringent mechanisms of menopause established after 500 million years of evolution where each cell in each tissue is the master of its sex steroid exposure.
本研究纳入了年龄在40 - 80岁、有中度至重度外阴阴道萎缩(VVA)症状的女性的数据。这些女性每天阴道内给予0.50%(6.5mg)脱氢表雄酮(DHEA;普拉睾酮),持续12周(n = 723;ITT - S人群),并与安慰剂组(n = 266;ITT - S人群)进行比较。为此,在第1天和第12周,按照美国食品药品监督管理局(FDA)指南[1 - 6]进行验证后,通过液相色谱 - 串联质谱法(LC - MS/MS)测定血清类固醇水平(DHEA、硫酸脱氢表雄酮(DHEA - S)、雄甾 - 5 - 烯 - 3β,17β - 二醇(5 - 二醇)、睾酮、双氢睾酮(DHT)、雄烯二酮(4 - 二酮)、雌酮(E1)、雌二醇(E2)、硫酸雌酮(E1 - S)、雄酮葡糖苷酸(ADT - G)和雄烷 - 3α,17β - 二醇17 - 葡糖苷酸(3α - 二醇 - 17G))。根据内分泌学机制,DHEA仅在细胞内转化为活性性激素,这些激素在局部发挥作用并失活,然后以葡糖苷酸或硫酸化代谢产物的形式释放,由肾脏和肝脏清除。阴道内给予DHEA后,所有性激素水平均保持在绝经后正常范围内。血清雌二醇是最相关的性激素,治疗12周后测得其水平为3.36pg/ml(cITT - S人群),比绝经后正常水平4.17pg/ml低19%。另一方面,血清E1 - S是全球雌激素活性最公认的标志物,12周时平均值为209pg/ml,而绝经后正常女性为220pg/ml。此外,血清ADT - G作为雄激素的主要代谢产物,也保持在绝经后正常范围内。目前的数据表明,低剂量每日阴道内给予(6.5mg)DHEA(普拉睾酮)对VVA的症状和体征有效,能够在不产生全身暴露的情况下达到预期的局部疗效,这与经过5亿年进化形成的严格绝经机制相一致,即每个组织中的每个细胞都能控制自身的性激素暴露。